KNAX was redesigned in 2020 to develop the first-in-class diagnostic methods to address unmet medical needs. We are expanding range of patient indications from cancer to infectious diseases and striving
practical strategies for improving diagnosis and patient outcomes. Besides research and development, KNAX offers products and CDMO/CRO services through diverse affiliates.
